Insider Selling: Atara Biotherapeutics, Inc. (ATRA) Director Sells 1,184 Shares of Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Director Carol Giltner Gallagher sold 1,184 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $14.20, for a total transaction of $16,812.80. Following the completion of the transaction, the director now owns 110,105 shares in the company, valued at $1,563,491. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Shares of Atara Biotherapeutics, Inc. (NASDAQ ATRA) opened at $14.60 on Tuesday. Atara Biotherapeutics, Inc. has a 52-week low of $11.80 and a 52-week high of $23.00.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.02) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.05). sell-side analysts forecast that Atara Biotherapeutics, Inc. will post -4 earnings per share for the current fiscal year.

Several brokerages have recently commented on ATRA. Canaccord Genuity set a $47.00 price objective on shares of Atara Biotherapeutics and gave the stock a “buy” rating in a report on Monday, August 7th. BidaskClub lowered shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Goldman Sachs Group reiterated a “neutral” rating and set a $20.00 target price on shares of Atara Biotherapeutics in a report on Friday, October 6th. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating and set a $15.00 target price on the stock in a report on Tuesday, August 22nd. Finally, Jefferies Group reiterated a “buy” rating and set a $30.00 target price on shares of Atara Biotherapeutics in a report on Thursday, October 5th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. Atara Biotherapeutics presently has a consensus rating of “Hold” and an average target price of $24.40.

Several large investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP grew its position in shares of Atara Biotherapeutics by 2.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock valued at $304,000 after buying an additional 610 shares during the last quarter. American International Group Inc. grew its position in shares of Atara Biotherapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 948 shares during the last quarter. Teachers Advisors LLC grew its position in shares of Atara Biotherapeutics by 2.4% in the 2nd quarter. Teachers Advisors LLC now owns 47,156 shares of the biotechnology company’s stock valued at $660,000 after buying an additional 1,110 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Atara Biotherapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock valued at $285,000 after buying an additional 1,369 shares during the last quarter. Finally, Alps Advisors Inc. grew its position in shares of Atara Biotherapeutics by 5.8% in the 2nd quarter. Alps Advisors Inc. now owns 26,274 shares of the biotechnology company’s stock valued at $368,000 after buying an additional 1,445 shares during the last quarter. 85.61% of the stock is currently owned by institutional investors.

WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/05/carol-giltner-gallagher-sells-1184-shares-of-atara-biotherapeutics-inc-atra-stock.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply